Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa

Staedt, J.; Wassmuth, F; Ziemann, Ulf; Hajak, Göran; Rüther, Eckart; Stoppe, Gabriela

doi:10.1007/bf01277664

Cited by 65 publications

(34 citation statements)

References 20 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Placebo-controlled trials also demonstrate the efficacy of the DAs pramipexole [77], pergolide [78][79][80][81], bromocriptine [82], apomorphine [83], cabergoline [84], and rotigotine [84], and of the dopamine precursor levodopa [85][86][87]. Levodopa was inferior to pergolide in the only controlled comparative trial among dopaminergic medications [79].…”

Section: Treatment Of Restless Legs Syndromementioning

confidence: 97%

See 1 more Smart Citation

Restless legs syndrome

Ondo

2005

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

Restless legs syndrome is a very common and still under-diagnosed neurologic condition that can cause severe morbidity. The pathology centers around central nervous system iron homeostatic dysregulation with subsequent alterations in dopaminergic functioning. Genetic studies will hopefully soon identify specific abnormalities. Treatment of restless legs syndrome with dopaminergic medications is highly effective, although augmentation may occur eventually and require dosing flexibility.

show abstract

Section: Treatment Of Restless Legs Syndromementioning

confidence: 97%

“…Levodopa was inferior to pergolide in the only controlled comparative trial among dopaminergic medications [79]. It is also felt to have greater potential for augmentation [88].…”

Section: Treatment Of Restless Legs Syndromementioning

confidence: 99%

Restless legs syndrome

Ondo

2005

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

show abstract

“…Four of these trials are placebo-controlled mostly giving levodopa/DDCI as a single bedtime dose for nocturnal RLS symptoms [83][84][85]88]. Two trials, including an open study, have investigated the sustained release formulation of levodopa [87,89], while four trials have investigated levodopa compared to other agents such as pergolide [86], valproic acid [89], gabapentin [91], and cabergoline [90]. The dosages range between 100-300 mg per night as a single dose, with a second dose three hours after bedtime or in combination with a sustained-release formulation.…”

Section: ■ Levodopa/decarboxylase Inhibitor (Ddci)mentioning

confidence: 99%

“…Eight randomized controlled trials [83][84][85][86][87][88][89][90] are available to prove the efficacy of levodopa/DDCI in RLS therapy. Four of these trials are placebo-controlled mostly giving levodopa/DDCI as a single bedtime dose for nocturnal RLS symptoms [83][84][85]88].…”

Section: ■ Levodopa/decarboxylase Inhibitor (Ddci)mentioning

confidence: 99%

Recent advances in the diagnosis, genetics and treatment of restless legs syndrome

2009

View full text Add to dashboard Cite

Knowledge of restless legs syndrome (RLS) has greatly increased in recent years due to the many advances that have been made in diagnosis, management and genetics. Tools have been developed that facilitate the diagnosis and treatment of RLS, in particular the essential diagnostic criteria for RLS have been refined, severity scales (IRLS, RLS-6, JHSS) have been developed, as have instruments that improve diagnostic accuracy and assess for specific aspects of RLS such as augmentation. These newly developed tools have been used in recent population-based studies, which have provided a greater understanding of the epidemiology of RLS, and also within patient-based trials. As far as the genetics of RLS is concerned, linkage studies in RLS families have revealed eight loci but no causally related sequence variant has yet been identified using this approach. Recent genome-wide association studies have identified variants within intronic or intergenic regions of MEIS1, BTBD9, and MAP2K5/LBXCOR1, and PTPRD, raising new pathological hypotheses for RLS. An overview on therapeutic options and recent trials is given based on evidence-based management strategies for this common disorder.

show abstract

“…Most reports of benefit were observational with only a single small controlled study [77]. Pergolide was a second ergoline derivative that was found to be effective in 4 controlled studies that included up to 100 RLS patients [74], and was shown to be superior to levodopa in some studies [78]. Carbergoline is a long-acting ergoline derivative with an elimination half life of 65 h that has been evaluated in controlled studies and shown to be beneficial in RLS [79].…”

Section: Dopamine Agonists For Rlsmentioning

confidence: 99%

Treatment of Restless Legs Syndrome

Comella¹

2014

Neurotherapeutics

View full text Add to dashboard Cite

Restless legs syndrome (RLS) is a common disorder diagnosed by the clinical characteristics of restlessness in the legs associated often with abnormal sensations that start at rest and are improved by activity, occurring with a diurnal pattern of worsened symptoms at night and improvement in the morning. RLS is the cause of impaired quality of life in those more severely afflicted. Treatment of RLS has undergone considerable change over the last few years. Several classes of medications have demonstrated efficacy, including the dopaminergic agents and the alpha-2-delta ligands. Levodopa was the first dopaminergic agent found to be successful. However, chronic use of levodopa is frequently associated with augmentation that is defined as an earlier occurrence of symptoms frequently associated with worsening severity and sometimes spread to other body areas. The direct dopamine agonists, including ropinirole, pramipexole, and rotigotine patch, are also effective, although side effects, including daytime sleepiness, impulse control disorders, and augmentation, may limit usefulness. The alpha-2-delta ligands, including gabapentin, gabapentin enacarbil, and pregabalin, are effective for RLS without known occurrence of augmentation or impulse control disorders, although sedation and dizziness can occur. Other agents, including the opioids and clonazepam do not have sufficient evidence to recommend them as treatment for RLS, although in an individual patient, they may provide benefit.

show abstract

Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa

Cited by 65 publications

References 20 publications

Restless legs syndrome

Restless legs syndrome

Recent advances in the diagnosis, genetics and treatment of restless legs syndrome

Treatment of Restless Legs Syndrome

Contact Info

Product

Resources

About